38
nanotimes
Companies Facts
Fab™ with an annual production capacity of around 850,000 solar modules will begin in early 2012. The production line will be installed in Asia.
Furthermore, Oerlikon has received approval from its lending banks to increase the company‘s ability to provide bank guarantees to customers in order to allow the Group to sustain Oerlikon‘s growth mo- mentum. As part of Oerlikon‘s efforts to further grow the business, the Group gained approval to amend its Syndicated Credit Facility Agreement with its lending banks. As a result of the strong order backlog in the Group‘s Textile Segment, which often results in longer lead times, Oerlikon‘s bank guarantee requirements on orders may exceed its current bank guarantee facilities. With this amendment, Oerlikon can raise the Group‘s bank guarantee facilities on customers‘ advance payments for orders. In addition, this approval allows Oerlikon to reduce its debt. The original Syndicated Credit Facility Agreement was announced in April 2010.
http://www.oerlikon.com
P
lasma-Therm, LLC has been awarded by equip- ment users as one of the 10 BEST 2011 Suppliers
of Chip Making Equipment and one of THE BEST 2011 Small Suppliers of Wafer Processing Equipment. Plasma-Therm, founded in 1974, is a global techno- logical leader for designing, manufacturing and sup- porting plasma etch and plasma enhanced chemical vapor deposition (PECVD) equipment to various high technology market segments and industries.
http://www.plasmatherm.com
P
lug Power Inc. (NASDAQ: PLUGD) has com- pleted the previously announced underwritten
public offering of 8,265,000 shares of its common stock and warrants to purchase an aggregate of 7,128,563 shares of common stock (which includes warrants to purchase an aggregate of 929,813 shares of common stock purchased by the underwriter pursuant to the exercise of its over-allotment option). The shares and the warrants were sold together as a fixed combination, with each combination consisting of one share of common stock and 0.75 of a warrant to purchase one share of common stock, at a price to the public of $2.42 per fixed combination for gross proceeds of approximately $20.0 million.
Net proceeds, after underwriting discounts and commissions and other estimated fees and expenses payable by Plug Power, and assuming the warrants are not exercised, were approximately $18.3 million.
http://www.plugpower.com
p
Sivida Corp. (NASDAQ: PSDV)(ASX: PVA) announced that its licensee, Alimera Sciences,
Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN®
for the treatment of
diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.
Alimera reported that according to the FDA’s classi- fication scheme, this will be a Class 2 resubmission. Under the Prescription Drug User Fee Act (PDUFA), FDA review of a Class 2 resubmission is expected to be completed within a six-month period beginning on the date that the resubmission is received.
11-05 :: May/June 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95